394 related articles for article (PubMed ID: 33227569)
1. A pilot randomized double-blind, placebo-controlled study on the effects of the topical application of pyridoxine on palmar-plantar erythrodysesthesia (PPE) induced by capecitabine or pegylated liposomal doxorubicin (PLD).
Charalambous A; Tsitsi T; Astras G; Paikousis L; Filippou E
Eur J Oncol Nurs; 2021 Feb; 50():101866. PubMed ID: 33227569
[TBL] [Abstract][Full Text] [Related]
2. A randomised controlled feasibility trial to evaluate Lawsonia inermis (henna)'s effect on palmar-plantar erythrodysesthesia induced by capecitabine or pegylated liposomal doxorubicin.
Stavrinou M; Tsitsi T; Astras G; Paikousis L; Charalambous A
Eur J Oncol Nurs; 2021 Apr; 51():101908. PubMed ID: 33626423
[TBL] [Abstract][Full Text] [Related]
3. Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08).
Templeton AJ; Ribi K; Surber C; Sun H; Hsu Schmitz SF; Beyeler M; Dietrich D; Borner M; Winkler A; Müller A; von Rohr L; Winterhalder RC; Rochlitz C; von Moos R; Zaman K; Thürlimann BJ; Ruhstaller T;
Breast; 2014 Jun; 23(3):244-9. PubMed ID: 24656636
[TBL] [Abstract][Full Text] [Related]
4. Clinical risk factors of PEGylated liposomal doxorubicin induced palmar plantar erythrodysesthesia in recurrent ovarian cancer patients.
Ko EM; Lippmann Q; Caron WP; Zamboni W; Gehrig PA
Gynecol Oncol; 2013 Dec; 131(3):683-8. PubMed ID: 24096112
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters.
Ajgal Z; Chapuis N; Emile G; Cessot A; Tigaud JM; Huillard O; Boudou-Rouquette P; Fontenay M; Goldwasser F; Alexandre J
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1033-9. PubMed ID: 26420236
[TBL] [Abstract][Full Text] [Related]
6. Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia.
Chalermchai T; Tantiphlachiva K; Suwanrusme H; Voravud N; Sriuranpong V
Asia Pac J Clin Oncol; 2010 Sep; 6(3):155-60. PubMed ID: 20887495
[TBL] [Abstract][Full Text] [Related]
7. Prevention of palmoplantar erythrodysesthesia in patients treated with pegylated liposomal doxorubicin (Caelyx®).
Jung S; Sehouli J; Chekerov R; Kluschke F; Patzelt A; Fuss H; Knorr F; Lademann J
Support Care Cancer; 2017 Nov; 25(11):3545-3549. PubMed ID: 28653108
[TBL] [Abstract][Full Text] [Related]
8. Incidence of palmar-plantar erythrodysesthesia in pretreated and unpretreated patients receiving pegylated liposomal doxorubicin.
Miolo G; Baldo P; Bidoli E; Lombardi D; Scalone S; Sorio R; Veronesi A
Tumori; 2009; 95(6):687-90. PubMed ID: 20210230
[TBL] [Abstract][Full Text] [Related]
9. A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients.
von Gruenigen V; Frasure H; Fusco N; DeBernardo R; Eldermire E; Eaton S; Waggoner S
Cancer; 2010 Oct; 116(20):4735-43. PubMed ID: 20629022
[TBL] [Abstract][Full Text] [Related]
10. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome).
Lorusso D; Di Stefano A; Carone V; Fagotti A; Pisconti S; Scambia G
Ann Oncol; 2007 Jul; 18(7):1159-64. PubMed ID: 17229768
[TBL] [Abstract][Full Text] [Related]
11. Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study.
Meadows KL; Rushing C; Honeycutt W; Latta K; Howard L; Arrowood CA; Niedzwiecki D; Hurwitz HI
Support Care Cancer; 2015 May; 23(5):1311-9. PubMed ID: 25341548
[TBL] [Abstract][Full Text] [Related]
12. Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.
Tanyi JL; Smith JA; Ramos L; Parker CL; Munsell MF; Wolf JK
Gynecol Oncol; 2009 Aug; 114(2):219-24. PubMed ID: 19446868
[TBL] [Abstract][Full Text] [Related]
13. Pyridoxine as prophylactic therapy for palmar-plantar erythrodysesthesia associated with administration of pegylated liposomal doxorubicin (caelyx): a single-center experience.
Rossi D; Catalano G
Oncology; 2007; 73(3-4):277-8. PubMed ID: 18424894
[No Abstract] [Full Text] [Related]
14. A dose escalation study of pegylated liposomal Doxorubicin (caelyx) in combination with capecitabine (xeloda) in patients with refractory solid tumors.
Maltezos E; Amarantidis K; Trichas M; Vasiliadis M; Toromanidou M; Chatzaki E; Karayiannakis A; Tsaroucha A; Romanidis K; Kakolyris S
Oncology; 2005; 69(6):463-9. PubMed ID: 16374040
[TBL] [Abstract][Full Text] [Related]
15. Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.
Yap YS; Kwok LL; Syn N; Chay WY; Chia JWK; Tham CK; Wong NS; Lo SK; Dent RA; Tan S; Mok ZY; Koh KX; Toh HC; Koo WH; Loh M; Ng RCH; Choo SP; Soong RCT
JAMA Oncol; 2017 Nov; 3(11):1538-1545. PubMed ID: 28715540
[TBL] [Abstract][Full Text] [Related]
16. Elevated body mass index does not increase the risk of palmar-plantar erythrodysesthesia in patients receiving pegylated liposomal doxorubicin.
Gordinier ME; Dizon DS; Fleming EL; Weitzen S; Schwartz J; Parker LP; Granai CO
Gynecol Oncol; 2006 Oct; 103(1):72-4. PubMed ID: 16494932
[TBL] [Abstract][Full Text] [Related]
17. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer.
Al-Batran SE; Meerpohl HG; von Minckwitz G; Atmaca A; Kleeberg U; Harbeck N; Lerbs W; Hecker D; Sehouli J; Knuth A; Jager E
Oncology; 2006; 70(2):141-6. PubMed ID: 16645327
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG.
Smorenburg CH; de Groot SM; van Leeuwen-Stok AE; Hamaker ME; Wymenga AN; de Graaf H; de Jongh FE; Braun JJ; Los M; Maartense E; van Tinteren H; Nortier JWR; Seynaeve C
Ann Oncol; 2014 Mar; 25(3):599-605. PubMed ID: 24504445
[TBL] [Abstract][Full Text] [Related]
19. Efficient prevention strategy against the development of a palmar-plantar erythrodysesthesia during chemotherapy.
Lademann J; Martschick A; Kluschke F; Richter H; Fluhr JW; Patzelt A; Jung S; Chekerov R; Darvin ME; Haas N; Sterry W; Zastrow L; Sehouli J
Skin Pharmacol Physiol; 2014; 27(2):66-70. PubMed ID: 23969763
[TBL] [Abstract][Full Text] [Related]
20. The use of cod liver oil by patients receiving pegylated liposomal doxorubicin is associated with a lack of severe palmar-plantar erythrodysesthesia.
Kanis M; Kesterson JP; Lele S
Eur J Gynaecol Oncol; 2009; 30(4):387-8. PubMed ID: 19761128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
